Fierce Biotech February 25, 2024
Max Bayer

Johnson & Johnson is closing a nearly 200,000 square-foot R&D outpost in Brisbane, California, less than 18 months after it opened, according to multiple sources familiar with the decision.

A J&J spokesperson confirmed the closure in a statement sent to Fierce Biotech Sunday evening, saying that the company “will continue to have a significant footprint in California” across its pharma and medtech units, plus the establishment of a “new California Innovation Center.”

Sources familiar with the matter told Fierce that the decision to close the San Francisco Bay Campus (SFBC) was relayed to staff on Thursday. The site recently hosted J&J’s Gene Therapy Summit on February 15.

“As the world’s largest and most diversified healthcare products company, we continually...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
First Comprehensive Review of SMA Drugs Offers Long-Term Insights, Outcome Gaps
Health Rounds: Next Generation Lilly Weight-loss Drug Shows Added Heart, Liver Benefits
Drugmaker might be 1st healthcare company to top $1 trillion valuation
Prescription drug spending grew even after rebates
Remote monitoring and pharmacist helps improve hard-to-control blood pressure, research shows

Share This Article